About

“NeuroMax” is a private biotechnology company, founded with the purpose to develop and launch in the Russian market innovative products for treatment of central and peripheral nervous system diseases. Since 2011 “NeuroMax” has become Skolkovo resident and participant of Technology platform “Medicine of the Future”.To date the Company develops two compounds BNV-222 and AQU-005.

News

Maxwell Biotech Venture Fund's portfolio company NeuroMax Ltd and its development partner, Aquilus Pharmaceuticals, Inc today announced the start of Phase 1, open label, prospective, safety, tolerability and pharmacokinetics study of AQU-005 for the treatment of chronic neuropathic pain. Recruitment in the clinical study is underway and is expected to enroll up to 24 healthy adult volunteers in Russia.

Maxwell Biotech Venture Fund's portfolio company NeuroMax Ltd and its development partner, Aquilus Pharmaceuticals, Inc today announced the start of Phase 1, open label, prospective, safety, tolerability and pharmacokinetics study of AQU-005 for the treatment of chronic neuropathic pain. Recruitment in the clinical study is underway and is expected to enroll up to 24 healthy adult volunteers in Russia.

NeuroMax has successfully completed pre-clinical studies of AQU-005, a very potent, dual active inhibitor of matrix metalloprotease (MMP) type 2 and 9. The drug demonstrated favorable safety profile and high efficacy in animal models of neuropathic pain in comparison with the ‘gold standard’, gabapentin.

“We are very pleased that AQU-005 has moved into clinical development and hope that the positive results that we have observed preclinically will translate into the clinic and ultimately help the millions of people suffering from different types of neuropathic pain”, — said Irving Sucholeiki, President&CEO of the biopharmaceutical company, Aquilus Pharmaceuticals.

“We are excited to initiate clinical development of AQU-005 in this area of high unmet medical need. We are planning to start proof of concept clinical trials in patients with neuropathic pain in Q4 2016”, — said Alexander Alexandrov, Medical Director of Maxwell Biotech Group.

About AQU-005

AQU-005 drug is a first in class MMP-2 and 9 inhibitor that blocks pain at both early and late phases via a totally novel mechanism of action. 

About NeuroMax

NeuroMax Ltd is a biotechnology company, founded in 2010, with the purpose to develop and market launch innovative products for the treatment of central and peripheral nervous system diseases in Russia.

About Maxwell Biotech Venture Fund

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with participation of the Russian Venture Company. MBVF portfolio companies have nine innovative clinical drug candidates in development.

Press contacts

Maxwell Biotech Group,  Natalia Bakrenko, +7 (495) 726-52-53, bakrenko@ammaxwell.ru

NeuroMax Ltd and its development partner, Bionevia LLC, today announced the completion of the enrollment within NM-ARI-231, a Phase 2b randomized, double-blind, placebo-controlled twelve month, chronic efficacy and safety study of BNV-222 (diepalrestat) in adult subjects with diabetic peripheral neuropathy. Four hundred (400) subjects were enrolled in 27 sites in Russia.  The ongoing Phase 2b clinical trial evaluates efficacy on motor nerve conduction velocity, clinical outcomes, and visual acuity.

NeuroMax Ltd and its development partner, Bionevia LLC, today announced the completion of the enrollment within NM-ARI-231, a Phase 2b randomized, double-blind, placebo-controlled twelve month, chronic efficacy and safety study of BNV-222 (diepalrestat) in adult subjects with diabetic peripheral neuropathy. Four hundred (400) subjects were enrolled in 27 sites in Russia.  The ongoing Phase 2b clinical trial evaluates efficacy on motor nerve conduction velocity, clinical outcomes, and visual acuity.

"While there are many drugs available to patients and physicians for the treatment of the symptoms of this disease, there are no therapies available to change the rate of progression of the underlying disease. This drug holds the promise to have a meaningful effect on the outcome of the major complications of Type 2 diabetes," — said Vera Bril, MD, Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at Mount Sinai Hospital, and the Principal Investigator of the Phase 2b study.

 “Assuming a positive trial outcome, Bionevia is targeting an End of Phase 2 Meeting with the FDA for the second half of 2017 where we hope to establish a clinical path forward for approval in the US”, — said Timothy Barberich, Chairman of Bionevia.

"Together with previously conducted supporting preclinical and clinical studies of BNV-222, which showed a favorable safety profile, the companies believe that the current Phase 2b trial results will enable the filing and approval for marketing in Russia", — said Julia Moskot, NeuroMax Program Director.

NeuroMax, Ltd a Russian private biotech company, financed by Maxwell Biotech Venture Fund, which was set up with the participation of RVC, has announced the launch of Phase Ib clinical trial of its pharmaceuticals NM-IA-001 (BNV-222), intended for the pathogenetic treatment of diabetic neuropathy
 
NeuroMax was founded in 2010 in order to develop and market innovative drugs for treatment of CNS and PNS diseases in close partnership with the US biotechnology company BioNevia Pharmaceuticals Inc.
 
NeuroMax, Ltd a Russian private biotech company, financed by Maxwell Biotech Venture Fund, which was set up with the participation of RVC, has announced the launch of Phase Ib clinical trial of its pharmaceuticals NM-IA-001 (BNV-222), intended for the pathogenetic treatment of diabetic neuropathy
 
NeuroMax was founded in 2010 in order to develop and market innovative drugs for treatment of CNS and PNS diseases in close partnership with the US biotechnology company BioNevia Pharmaceuticals Inc.
 
The clinical study, conducted at specialized medical centers in Moscow and Yaroslavl, is expected to last 3 months and represents a “Double-blind, placebo-controlled, randomized study of safety and pharmacokinetics of NM-IA-001 (BNV-222) (choline diepalrestat) at doses of 150 mg and 300 mg in subjects with diabetic peripheral neuropathy (DPN)”.
 
Nowadays there are no drugs for pathogenetic treatment of diabetes complications, such as NM-IA-001 (BNV-222). The new drug is a low-molecular inhibitor of aldose reductase ferment. This drug slows down diabetic neuropathy which is its main therapeutic indication. The drug can also be used to treat other diabetic complications such as diabetic nephropathy and retinopathy.
 
About NeuoMax
NeuroMax, Ltd is a Russian private biotech company, financed by Maxwell Biotech Venture Fund, set up with participation of RVC. The company was founded in 2010 in order to develop and market innovative drugs, intended for fighting against the central and peripheral nervous system diseases. NeuroMax, Ltd., member of the technological holding “Maxwell Biotech Group”, is a resident of the Biomed Cluster at Skolkovo Innovation Center and a member of the Technology Platform “The Medicine of the Future”. The first drug candidate NM-IA-0012 licensed from and developed in close partnership with the US biotechnology company BioNevia Pharmaceuticals Inc., is intended for the pathogenetic treatment of diabetic neuropathy.  
 
About Maxwell Biotech Group
Maxwell Biotech Group (MBG) is a development partner and financial resource for innovative biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts. The Group includes 10 innovative biotechnological projects, developing in the portfolio companies: OncoMax, Photonics, MetaMax, Infectex, NeuroMax, CardioNova, Hepatera, Osteros Biomedica, Eleventa.   All the group’s companies are the residents of the Biomed Cluster at Skolkovo Innovation Center and 5 of them are members of the Technology Platform “The Medicine of the Future”. 
 
For further information, please contact
Anna Sitnikova, Chief public relations Expert “Maxwell Biotech Group”
Tel. (495) 411-6992
 
About Russian Venture Company
RVC is a government fund of funds and a development institute of the Russian Federation, one of Russia's key tools in building its own national innovation system.
RVC was established by Russian Government on June 7, 2006 (Order No. 838-r). Its mission is to encourage Russia’s own VC industry and boost capital of VC funds. RVC’s role is that of a government fund of venture capital funds channeling public incentives to venture capital and financial support to the hi-tech sector, and of a Russian VC industry development institution.
RVC’s authorized capital — RUB 30 011 320 700 (about US$ 983.2 mln) — is 100% owned by the Federal Agency for State Property Management (Rosimuschestvo). RVC has backed 12 funds to a total capitalization of RUB 26.1 bln, its share amounting to RUB 16 bln. As on January 2013, RVC backed funds run a portfolio of 139 companies, invested capital totaling more than RUB 12.1 bln. 
 
For further information, please contact
Natalia Samokhvalova, Chief public relations Expert “Maxwell Biotech Group”
Tel. (495) 411-6992
 

 

On June 24, 2013 NeuroMax, Ltd and Aquilus Pharmaceuticals, Inc. announced the signing of the license agreement about transferring Neuromax the global rights to develop and market innovative drug AQU-005 for treatment of neuropathic pain. This has become the tenth deal in the portfolio of the Maxwell Biotech Venture Fund.
 
NeuroMax, Ltd, a portfolio company of Maxwell Biotech Venture Fund, created with the participation of RVC, was founded in 2010 in order to develop and market innovative drugs for treatment of CNS and PNS diseases.
 
On June 24, 2013 NeuroMax, Ltd and Aquilus Pharmaceuticals, Inc. announced the signing of the license agreement about transferring Neuromax the global rights to develop and market innovative drug AQU-005 for treatment of neuropathic pain. This has become the tenth deal in the portfolio of the Maxwell Biotech Venture Fund.
 
NeuroMax, Ltd, a portfolio company of Maxwell Biotech Venture Fund, created with the participation of RVC, was founded in 2010 in order to develop and market innovative drugs for treatment of CNS and PNS diseases.
 
The first product NM-IA-001 (BNV-222) licensed from and developed in close partnership with the US biotechnology company BioNevia Pharmaceuticals Inc., is intended for the pathogenetic treatment of diabetic neuropathy.  NeuroMax has successfully completed Phase Ia clinical trials on safety and tolerance and is ready to conduct Phase Ib clinical trials.
 
The new pharmaceuticals NM-AQU-005, added to portfolio of NeuroMax, is a small molecule inhibitor of matrix metalloproteinases (MMPs) and aimed at treatment of neuropathic pain of various genesis, including pain which patients, suffering from diabetic neuropathy, have. According to the developers, selective inhibition of two most perspective targets (MMP-2 and MMP-9) can afford to prevent the development of neuropathic pain, appearing under degenerative processes of the nerve cells. Dual mechanism of action gives ground to expect a long-lasting therapeutic effect. Preclinical studies have shown efficacy and safety of the drug on model systems. NeuroMax is planning to conduct clinical trials of its new drug NM-AQU-005 in 2014. 
 

 “Treatment of chronic neuropathic pain is one of the most difficult objectives of modern medicine, because the current pharmaceutical methods won’t afford to solve effectively this problem with maintenance of acceptable quality of patients’ life, - said Nikolay Golub, CEO of NeuroMax,- therefore we see good opportunities for this drug in the world markets and significant prospects  of our company’s development, which enhance its portfolio with drugs, offering the complex approach to the treatment of neurological diseases”. 

 
About NeuoMax
NeuroMax, Ltd is a Russian private biotech company, financed by Maxwell Biotech Venture Fund, set up with participation of RVC. The company was founded in 2010 in order to develop and market innovative drugs, intended for fighting against the central and peripheral nervous system diseases. NeuroMax, Ltd., member of the technological holding “Maxwell Biotech Group”, is a resident of the Biomed Cluster at Skolkovo Innovation Center and a member of the Technology Platform “The Medicine of the Future”. The first drug candidate NM-IA-0012 licensed from and developed in close partnership with the US biotechnology company BioNevia Pharmaceuticals Inc., is intended for the pathogenetic treatment of diabetic neuropathy.  
 
About Maxwell Biotech Group
Maxwell Biotech Group (MBG) is a development partner and financial resource for innovative biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts. The Group includes 10 innovative biotechnological projects, developing in the portfolio companies: OncoMax, Photonics, MetaMax, Infectex, NeuroMax, CardioNova, Hepatera, Osteros Biomedica, Eleventa.   All the group’s companies are the residents of the Biomed Cluster at Skolkovo Innovation Center and 5 of them are members of the Technology Platform “The Medicine of the Future”. 
 
For further information, please contact
Anna Sitnikova, Chief public relations Expert “Maxwell Biotech Group”
Tel. (495) 411-6992
 
About Russian Venture Company
RVC is a government fund of funds and a development institute of the Russian Federation, one of Russia's key tools in building its own national innovation system.
RVC was established by Russian Government on June 7, 2006 (Order No. 838-r). Its mission is to encourage Russia’s own VC industry and boost capital of VC funds. RVC’s role is that of a government fund of venture capital funds channeling public incentives to venture capital and financial support to the hi-tech sector, and of a Russian VC industry development institution.
RVC’s authorized capital — RUB 30 011 320 700 (about US$ 983.2 mln) — is 100% owned by the Federal Agency for State Property Management (Rosimuschestvo). RVC has backed 12 funds to a total capitalization of RUB 26.1 bln, its share amounting to RUB 16 bln. As on January 2013, RVC backed funds run a portfolio of 139 companies, invested capital totaling more than RUB 12.1 bln. 
 
For further information, please contact
Natalia Samokhvalova, Chief public relations Expert “Maxwell Biotech Group”
Tel. (495) 411-6992
 

 

NeuroMax has received permission from the Ministry of Health of the Russian Federation to conduct Phase Ib clinical trial to study the safety and pharmacokinetics of developed drug candidate NM-IA-001 (BNV-222, choline diepalrestat) in patients with diabetic polyneuropathy. This study is scheduled to start in May and will be conducted on the basis of specialized medical centers in Perm, Yaroslavl and Rostov-on-Don. The company has previously announced the successful completion of Phase Ia clinical trial conducted on the basis of the clinical center E.A.

NeuroMax has received permission from the Ministry of Health of the Russian Federation to conduct Phase Ib clinical trial to study the safety and pharmacokinetics of developed drug candidate NM-IA-001 (BNV-222, choline diepalrestat) in patients with diabetic polyneuropathy. This study is scheduled to start in May and will be conducted on the basis of specialized medical centers in Perm, Yaroslavl and Rostov-on-Don. The company has previously announced the successful completion of Phase Ia clinical trial conducted on the basis of the clinical center E.A. Wagner Perm State Medical Academy.

The new clinical study will be a “Double-blind, placebo-controlled, randomized study of the safety and pharmacokinetics BNV-222 (choline diepalrestat) at doses of 150 mg and 300 mg in patients with diabetic polyneuropathy”.

"The design of the new study will provide extensive information about the safety of our drug candidate and its pharmacokinetic properties, as well as give us the opportunity to select the appropriate dosage in order develop the best course of treatment in the future,” said Nikolay Golub, CEO of NeuroMax.

NeuroMax was created with investments from Maxwell Biotech Venture Fund founded with the participation of RVC.  NeuroMax develops and commercializes innovative drug products for the treatment of diseases of the central and peripheral nervous system. Drug candidate NM-IA-001 (BNV-222), licensed from and developed in close partnership with the U.S. biotechnology company BioNevia Pharmaceuticals Inc., is a small molecule inhibitor of the aldose reductase enzyme designed for the treatment of complications caused by diabetes. The main application of NM-IA-001 (BNV-222) is diabetic neuropathy, although additional focus will be centered on diabetic nephropathy and retinopathy.

NeuroMax has successfully completed Phase Ia clinical trials on the safety and pharmacokinetics of drug candidate NM-IA-001 (BNV-222) for patients with diabetic neuropathy. Previously approved by the Ministry of Health of the Russian Federation the study was conducted at the E.A. Wagner Perm State Medical Academy.

According to a preliminary report based on the results of the study, NM-IA-001 (BNV-222) is well-tolerated, safe, and can be recommended for further clinical trials for drug registration in the Russian Federation.

NeuroMax has successfully completed Phase Ia clinical trials on the safety and pharmacokinetics of drug candidate NM-IA-001 (BNV-222) for patients with diabetic neuropathy. Previously approved by the Ministry of Health of the Russian Federation the study was conducted at the E.A. Wagner Perm State Medical Academy.

According to a preliminary report based on the results of the study, NM-IA-001 (BNV-222) is well-tolerated, safe, and can be recommended for further clinical trials for drug registration in the Russian Federation.

"Analysis of the preliminary data obtained in our study confirms the good tolerability and safety profile of NM-IA-001 in all 18 patients who participated in this clinical trial and we hope that with these results we will be able to move in the near future to the next phase of clinical trials which will involve a larger number of patients and will expand the range of applicable drug doses,” said Nikolay Golub, CEO of NeuroMax.

NeuroMax was created with investments from Maxwell Biotech Venture Fund founded with the participation of RVC.  NeuroMax develops and commercializes innovative drug products for the treatment of diseases of the central and peripheral nervous system. Drug candidate NM-IA-001 (BNV-222), licensed from and developed in close partnership with the U.S. biotechnology company BioNevia Pharmaceuticals Inc., is a small molecule inhibitor of the aldose reductase enzyme designed for the treatment of complications caused by diabetes. The main application of NM-IA-001 (BNV-222) is diabetic neuropathy, although additional focus will be centered on diabetic nephropathy and retinopathy.

Previously, NeuroMax successfully completed a series of preclinical studies on the safety of NM-IA-001 (BNV-222), and the positive results from the study enabled the company to proceed with clinical trials. Should all phases of the clinical trials produce positive results, NM-IA-001 (BNV-222) may become the first medicine in Russia for mechanism-based therapy for serious complications due to diabetes.

On April 24, the NeuroMax, Ltd., a portfolio company of Maxwell Biotech Venture Fund, founded with the participation of RVC, received an authorization by the Ministry of Healthcare and Social Development of the Russian Federation to carry out clinical trials of its drug candidate NM-IA-001 (choline diepalrestat, BNV-222). 

On April 24, the NeuroMax, Ltd., a portfolio company of Maxwell Biotech Venture Fund, founded with the participation of RVC, received an authorization by the Ministry of Healthcare and Social Development of the Russian Federation to carry out clinical trials of its drug candidate NM-IA-001 (choline diepalrestat, BNV-222). 

With this authorization, NeuroMax can start studying the safety and pharmacokinetics of the drug in patients with diabetic polyneuropathy. The study will be carried out in the Ye.A. Vagner Perm State Medical Academy.

Nowadays, there are no drugs for pathogenetic treatment of diabetes complications, such as NM-IA-001 (BNV-222). The new drug candidate is a low-molecular inhibitor of aldose reductase ferment. This drug slows down diabetic neuropathy, which is the main indication for its administration. The drug can be also used to treat other diabetic complications, including diabetic nephropathy and retinopathy.

Last autumn the company successfully completed a series of preclinical trials of the efficiency and safety of NM-IA-001 (BNV-222), which showed high efficiency and considerable slowing down of the diabetic polyneuropathy. Due to this success, the company can proceed with the stage of the clinical trials of this drug. If all phases of the clinical trials show positive results, NM-IA-001 (BNV-222) may become the first drug in Russia for pathogenetic treatment of diabetic neuropathy.

Nikolay Golub, CEO of NeuroMax, “The studies are scheduled to start in early summer. We confidently expect positive results from the first phase of the study, and then we will start the second phase in the autumn. We do everything possible so that the new highly efficient drug could become available to Russian patients, suffering from diabetic neuropathy, as soon as possible.”

On November 29, 2011, the Digital October platform in Moscow hosted the IV Innovation Convention, in the course of which the Skolkovo Innovation Centre held a regular ceremony of awarding the resident status to its new participants. One of the start-ups, included into the Biomedical Cluster, was the NeuroMax, Ltd, a portfolio company of Maxwell Biotech Group.

On November 29, 2011, the Digital October platform in Moscow hosted the IV Innovation Convention, in the course of which the Skolkovo Innovation Centre held a regular ceremony of awarding the resident status to its new participants. One of the start-ups, included into the Biomedical Cluster, was the NeuroMax, Ltd, a portfolio company of Maxwell Biotech Group.

NeuroMax, Ltd is a private biotech company, financed by Maxwell Biotech Venture Fund, set up with participation of RVC. NeuroMax, Ltd was founded in 2010 in order to develop and market innovative drugs, intended for fighting against the central and peripheral nervous system diseases. It is the fifth portfolio company of Maxwell Biotech Group, that became a participant of the Skolkovo Innovation Centre in 2011.

Receiving the traditional symbols of the Innovation Centre participant, CEO of NeuroMax Nikolay Golub noted that he was very glad that the awarding ceremony was taking place in such a friendly and democratic atmosphere. He expressed hope that the further relations of NeuroMax and Skolkovo would develop in such an atmosphere.

The company has recently completed a series of preclinical trials of the efficiency and safety of the first developed drug NM-IA-001, aimed at treatment of diabetes complications, and plans to proceed with the stage of the clinical trials of this drug. If the clinical trials are successful, NM-IA-001 may become the first drug in Russia for the pathogenetic treatment of diabetic neuropathy.

Nowadays, there are no pathogenetic treatment drugs in the market of drugs, intended to treat diabetes complications. NM-IA-001 is a low-molecular inhibitor of an aldose reductase ferment. This drug considerably slows down diabetic neuropathy. The main indication of NM-IA-001 is distal diabetic polyneuropathy and it can be additionally used for treatment of other diabetic complications, including diabetic nephropathy and retinopathy.

Bionevia Pharmaceuticals, Inc., an American biotech company is a NeuroMax’ partner in product development.

 

Photo: Nikolay Golub, CEO of NeuroMax, (on the right) is receiving documents, confirming the status of a resident of the Skolkovo Innovation Centre Biomedical Cluster from Alexander Chernov, Skolkovo Innovation Centre (on the left)

In October the NeuroMax, Ltd private biotech company, financed by Maxwell Biotech Venture Fund, founded with the participation of RVC, obtained positive results of the preclinical trials of the efficiency and safety of the developed NM-IA-001 drug, which should become the first drug in Russia, intended for the pathogenetic treatment of diabetic neuropathy. These results enable the company to proceed with the stage of the clinical trials of this drug.

In October the NeuroMax, Ltd private biotech company, financed by Maxwell Biotech Venture Fund, founded with the participation of RVC, obtained positive results of the preclinical trials of the efficiency and safety of the developed NM-IA-001 drug, which should become the first drug in Russia, intended for the pathogenetic treatment of diabetic neuropathy. These results enable the company to proceed with the stage of the clinical trials of this drug.

According to Nikolay Golub, CEO of the NeuroMax, Ltd: “The results of the preclinical trials give every reason to believe that the high efficiency and safety of this drug will also be confirmed by the clinical studies, which are scheduled be to started in the beginning of 2012”.

Yan Ryazantsev, director of the investment and expertise department at RVC, noted: “The results of the studies of preclinical efficiency and toxicity justify our hopes and give confidence to the members of the team, developing the drug. Completion of the preclinical trials within a year is a rather good result for a new team. Now the company has to accomplish more complicated tasks. We hope that, using the expertise of the fund’s specialists, the company will manage to overcome all the difficulties within the framework of the agreed schedule and will achieve the set goals”.

Nowadays, there are no pathogenetic treatment drugs in the market of drugs, intended to treat diabetes complications. NM-IA-001, developed by NeuroMax, is a low-molecular inhibitor of aldose reductase ferment. This drug considerably slows down diabetic neuropathy. The main indication of this drug is diabetic distal polyneuropathy and it can be additionally used for treating other diabetic complications, including diabetic nephropathy and retinopathy.

More information about the results of the preclinical trials of the drug

For this moment NeuroMax has completed a series of pre-clinical studies, including the study of acute and subacute toxicity, allergenicity, pharmacokinetics, immunotoxicity, reproductive toxicity, mutagenicity, carcinogenicity and specific pharmacological activity.

On the basis of the results, obtained in animals, it is possible to conclude that in case of the intragastric intake of NM-IA-001 in a therapeutic and 10-fold intermediate dose, this drug does not have a toxic effect. Its administration does not lead to the development of pathologic changes in the general health condition and behavior of animals, does not have a toxic effect on the cardiovascular system, morphologic composition, biochemical and other properties of the peripheral blood, bone marrow, as well as on the functional state of the liver and kidneys, protein, carbohydrate, fat and electrolytic types of metabolism. This drug does not cause pathomorphological changes, which confirms good tolerability and relative harmlessness of the substance. The substance does not have a locally irritant effect in case of its multiple intragastric intake. The substance intake in a maximum 25-fold dose leads to a number of proved changes in the 90th day of intake. These changes include a slight reduction of the physical activity, changes in a number of hematological and biochemical parameters, slight increase of the mass coefficients and dystrophic changes in the liver, thymus and kidneys. However, these changes are not clinically significant.

Bionevia Pharmaceuticals, Inc., an American biotech company. is a NeuroMax’ partner in product development.